Webbplatsen kommer inte fungerar helt korrekt om er webbläsares JavaScript funktion är inaktiverad.
}
Effective treatment of hypothyroid

Prolevi Bio

Prolevi Bio develops a delayed release thyroid hormone formulation mimicking the circadian rhythm improving long-term side effects, overdosing and patient compliance.

Prolevi Bio

CEO:

Sahil Gupta

First investment year:

2022

Business sector:

Life Science, Drug development

Investment manager: Anna Gisselsson Visit website